Genesis’ CEO and co-founder Evan Feinberg sat down with a16z Bio + Health and Health’s Vijay Pande, PhD on this week’s episode of Bio Eats World to discuss AI in small-molecule drug design and the founding of Genesis, from Evan’s early days at Stanford to the company’s recent $200M series B. Listen to the podcast episode here: https://lnkd.in/g6-Zv-kQ
Advances in technology increasingly occur at the intersection of disciplines. Vijay Pande, PhD, recently spoke with Evan Feinberg, Founder and CEO of Genesis Therapeutics, about how he built a company that fosters collaboration between experts in complementary fields like biology, chemistry, and AI to supercharge discovery. Here’s how Evan does it at Genesis: 👉🏼 Engineers work hand-in-hand with biologists and chemists. Co-leads from complementary backgrounds partner on projects. 👉🏼 Created an internal platform called Nucleus which allows Genesis chemists to access the companies latest AI models. 👉🏼 Maintaining an approximate balance of 50% computational and 50% experimental scientists. The future of health will be driven by the synthesis of ideas at the intersections of expertise. Listen to Evan’s full episode on Bio Eats World here: https://lnkd.in/gdqZQZfK
